PDS0201

Product information
PDS0201 is an investigational vaccine designed for the prevention of tuberculosis. PDS0201 combines the utility of the Versamune^® platform with bacillus Mycobacterium tuberculosis (M. tuberculosis) antigens. The Versamune^® platform, due to its ability to induce both antibody and T-cell responses is being utilized to develop a vaccine to effectively prevent tuberculosis.

Disease state
Tuberculosis (TB) is the leading cause of death from a single infectious agent and is caused by the bacillus Mycobacterium tuberculosis, which is spread when people who are sick with TB expel bacteria into the air. About a quarter of the world’s population is infected with M. tuberculosis and thus at risk of developing TB disease. It has been reported that a total of 1.5 million people died from TB in 2018. Worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent (above HIV/AIDS).

Development status
PDS0201 is currently in pre-clinical development.

PDS0202

Product information
PDS0202 is an investigational vaccine designed for the prevention of a broad range of influenza strains. PDS0202 combines the utility of the Versamune^® platform with a mix of influenza antigens including conserved regions of the virus. The Versamune^® platform, due to its ability to induce both antibody and T-cell responses is being utilized to develop a vaccine that may have efficacy against any strain of the flu virus - including pandemic strains.

Disease state
Influenza or flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness and can result in death. Influenza is estimated to result in about 3 to 5 million cases of severe illness, and about 290,000 to 650,000 respiratory deaths globally. Some strains of influenza are known to have strong pandemic potential.

Development status
PDS0202 is currently in pre-clinical development.

PDS0203

Product information

PDS0203 is an investigational vaccine designed for the prevention of COVID-19. PDS0203 combines the utility of the Versamune^® platform with a recombinant native Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protein recognizable by our immune system (antigen). The Versamune^® platform, due to its unique ability to induce both antibody and T-cell responses is being utilized to develop a vaccine that may more effectively prevent COVID-19.

Disease state
In January of 2020 the world saw the emergence of the COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared COVID-19 a global health emergency in January of 2020. Within three months of initial discovery COVID-19 was declared a global pandemic, reflecting alarming levels of spread and severity and resulting in unprecedented action by local and national governments to restrict the movement of citizens to contain the spread.

Development status
PDS0203 is currently in pre-clinical development.